natgillin/translations-raw huggingface dataset:
Therefore, an additional non-hormonal contraceptive method and regular pregnancy tests should be considered during treatment (see section 4.5).
Zato je treba razmisliti o dodatni nehormonski kontracepciji in rednem opravljanju testov nosečnosti med zdravljenjem (glejte poglavje 4.5).
Therefore, an alternative method of effective contraception should be used if the woman patient is using hormonal contraceptives (see section 4.5).
Če ženska uporablja hormonsko kontracepcijo, je treba uporabiti dodatno metodo učinkovite kontracepcije (glejte poglavje 4.5).
Therefore, an alternative, effective and safe method of contraception should be used during treatment.
Zato je treba med zdravljenjem uporabiti drug učinkovit in varen način kontracepcije.
Therefore, antimicrobial prophylaxis for Pneumocystis carinii pneumonia should be administered for the first 12 months following transplantation.
Zato je treba prvih 12 mesecev po presaditvi uporabljati protimikrobno profilakso za pljučnico, ki jo povzroča Pneumocystis carinii.
Therefore, any patient treated with doxorubicin should be kept under haematological supervision.
Zato morate vse bolnike, zdravljene z doksorubicinom, hematološko nadzorovati.
Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolised by these enzymes.
Za apiksaban se torej ne pričakuje, da bi spremenil presnovni očistek sočasno uporabljenih zdravil, ki se presnavljajo preko teh encimov.
Therefore, Aptivus should be used with caution, and with increased monitoring frequency, in patients with mild hepatic impairment (Child- Pugh Class A).
Zdravilo Aptivus moramo pri bolnikih z blago jetrno okvaro (stopnje A po Child-Pughovi ravrstitvi) uporabljati previdno in zdravljenje pogosteje spremljati.
Therefore, Aptivus should be used with caution, and with increased monitoring frequency, in patients with mild hepatic impairment (Child- Pugh Class A).
Zdravilo Aptivus moramo pri bolnikih z blago jetrno okvaro (stopnje A po Child-Pughovi razvrstitvi) uporabljati previdno in zdravljenje pogosteje spremljati.
Therefore, as dose adjustments of these may be necessary, it is recommended that separate preparations of abacavir, lamivudine and zidovudine be administered to patients with reduced renal function (creatinine clearance  50 ml/min).
Ker bo tako verjetno potrebno odmerek teh dveh učinkovin prilagoditi, je pri bolnikih z zmanjšanim delovanjem ledvic (kreatininski očistek ≤ 50 ml/min) priporočljivo uporabljati abakavir, lamivudin in zidovudin kot samostojna zdravila.
Therefore, as some viruses are excreted in human milk, the vaccine should not be used during breast- feeding.
Ker se nekateri virusi pri človeku izločajo v materino mleko, se tega cepiva med nosečnostjo ne sme uporabljati.
Therefore, as with any intrathecal cytotoxic therapy, consideration should be given to the need for assessment of CSF flow before treatment is started.
Zato je kot pri vsakem intratekalnem citotoksičnem zdravljenju treba premisliti, ali je pred začetkom zdravljenja treba oceniti stanje pretoka cerebrospinalne tekočine.
Therefore, avoid consumption of alcohol and medicines containing alcohol when taking Synjardy (see section 4, ‘Possible side effects’).
Če jemljete zdravilo Synjardy, ne uživajte alkohola in ne uporabljajte zdravil, ki ga vsebujejo (glejte poglavje 4 “Možni neželeni učinki”).
Therefore, based on results from animal studies and the mechanism of action of irinotecan, ONIVYDE should not be used during pregnancy unless clearly necessary.
Zato na podlagi rezultatov študij na živalih in mehanizma delovanja irinotekana zdravila ONIVYDE ne smemo uporabljati med nosečnostjo, razen če je nujno potrebno.
Therefore, based on the safety profile in Intrinsa, which requires the submission of 6 monthly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
Zato je Odbor za zdravila za uporabo v humani medicini na podlagi varnostnega profila zdravila Intrinsa, za katerega je treba periodično poročilo o varnosti zdravila predložiti vsakih 6 mesecev, odločil, da mora imetnik dovoljenja za promet z zdravilom čez 5 let predložiti eno dodatno podaljšanje dovoljenja za promet z zdravilom.
Therefore, based on the safety profile in Livensa, which requires the submission of 6 monthly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
Zato je Odbor za zdravila za uporabo v humani medicini na podlagi varnostnega profila zdravila Livensa, za katerega je treba periodično poročilo o varnosti zdravila predložiti vsakih 6 mesecev, odločil, da mora imetnik dovoljenja za promet z zdravilom čez 5 let predložiti eno dodatno podaljšanje dovoljenja za promet z zdravilom.
Therefore, based upon the safety profile of ChondroCelect, which requires the submission of 1- yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years’ time.
Zato je na podlagi varnostnega profila zdravila ChondroCelect, ki zahteva predložitev vsakoletnih PSUR, odbor CHMP sklenil, da mora imetnik dovoljenja za promet predložiti eno dodatno vlogo za podaljšanje v času 5 let.
Therefore, based upon the safety profile of Zoely, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.
Odbor CHMP je na podlagi varnostnega profila zdravila Zoely zaključil, da mora imetnik dovoljenja za promet z zdravilom predložiti eno dodatno vlogo za podaljšanje po 5 letih.
Therefore, because of the known severe teratogenic effects of the product, during treatment with thalidomide and for 1 week after stopping the treatment, male patients must use condoms if their partner is pregnant or is of childbearing potential not using effective contraception (see section 4.4).
Zato morajo moški bolniki zaradi znanih resnih teratogenih učinkov zdravila med zdravljenjem s talidomidom in 1 teden po prekinitvi zdravljenja uporabljati kondom, če je njihova partnerica noseča ali v rodni dobi in ne uporablja zanesljive kontracepcijske metode (glejte poglavje 4.4).
Therefore, because of the risk of therapeutic failure, fruit juice should not be taken together with Rasilez.
Ker bi torej lahko prišlo do zmanjšanja terapevtskega učinka, se sadnega soka ne sme uživati skupaj z zdravilom Rasilez.
Therefore, Benlysta should be administered in an environment where resources for managing such reactions are immediately available.
Zato je treba zdravilo Benlysta dajati v okolju, kjer je nemudoma na voljo vse potrebno za obvladanje takšnih reakcij.
Therefore, breast-feeding may be continued during the vaccination schedule.
Med cepljenjem z obema odmerkoma cepiva torej lahko nadaljujete z dojenjem.
Therefore, breastfeeding may be considered in breast- feeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Zato ženske, ki prejemajo lamivudin zaradi HBV, lahko dojijo, vendar je treba pri odločitvi o tem upoštevati koristi dojenja za otroka in koristi zdravljenja za žensko.
Therefore, Brintellix should be introduced cautiously in patients who have a history of seizures or in patients with unstable epilepsy (see section 4.5).
Zato je treba zdravilo Brintellix pri bolnikih, ki so že imeli epileptične napade in bolnikih z nestabilno epilepsijo, uvajati previdno (glejte poglavje 4.5).
Therefore, careful clinical monitoring is advised in these patients (see section 5.2).
Zato je pri tej skupini bolnikov priporočljivo natančno klinično nadziranje (glejte poglavje 5.2).
Therefore, caution is advised when daptomycin is co- administered with any other medicinal product known to reduce renal filtration.
Zaradi tega priporočamo previdnost pri sočasnem dajanju daptomicina in katerega koli drugega zdravila, za katerega je znano, da zmanjšuje ledvično funkcijo.
Therefore, caution is recommended when administering imatinib with CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporin, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine).
Zato je pri uporabi imatiniba skupaj s substrati CYP3A4 z ozko terapevtsko širino (na primer s ciklosporinom, pimozidom, takrolimusom, sirolimusom, z ergotaminom, diergotaminom, s fentanilom, z alfentanilom, s terfenadinom, z bortezomibom, docetaksel in s kinidinom).
Therefore, caution is recommended when co-administering Senshio with fluconazole.
Zato se pri sočasni uporabi zdravila Senshio s flukonazolom priporoča previdnost.
Therefore, caution is recommended when driving or operating machines.
Zato se pri vožnji ali upravljanju s stroji priporoča previdnost.
Therefore, caution is warranted when dasatinib is coadministered with CYP3A4 substrates of narrow therapeutic index, such as astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine) (see section 4.5).
Pri sočasnem zdravljenju z dasatinibom in substrati za CYP3A4 z ozkim terapevtskim indeksom, kot so astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil ali alkaloidi ergot (ergotamin, dihidroergotamin) je potrebna previdnost (glejte poglavje 4.5).
Therefore, caution should be applied when co-administering Eurartesim with any CYP3A4-inhibitor and ECG monitoring should be considered.
Zato je pri sočasnem dajanju zdravila Eurartesim s katerim koli zaviralcem CYP3A4 potrebna previdnost in v poštev pride spremljanje EKG.
Therefore, caution should be exercised if telavancin is given to subjects with severe hepatic impairment.
Zato je potrebna previdnost, kadar se telavancin daje bolnikom s hudo okvaro jeter.
Therefore, caution should be exercised if these drugs are combined with Dacogen.
Pri kombiniranju teh zdravil z zdravilom Dacogen je zato potrebna previdnost.
Therefore, caution should be exercised in patients receiving other medicines metabolised by the liver.
Zato je potrebna previdnost pri bolnikih, ki prejemajo druga zdravila, ki jih presnavljajo jetra.
Therefore, caution should be exercised when aliskiren is administered with ketoconazole or other moderate pgp inhibitors (itraconazol, clarithromycin, telithromycin, erythromycin, amiodarone).
Zato je potrebna previdnost pri sočasni uporabi aliskirena s ketokonazolom ali z drugimi zmernimi zaviralci
Therefore, caution should be exercised when OPTISON is administered to breast-feeding women.
Zato je pri dajanju kontrastnega sredstva OPTISON doječim materam potrebna previdnost.
Therefore, caution should be exercised when OPTISON is administered to nursing women.
Zato je potrebna previdnost, ko se kontrastno sredstvo OPTISON uporablja pri doječih materah.
Therefore, caution should be exercised when potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered to Parkinson’s disease patients being treated with Tasmar and levodopa preparations.
Zato je potrebna previdnost kadar močne zaviralce ponovnega privzema noradrenalina, kot so dezipramin, maprotilin ali venlafaksin, dajemo bolnikom s Parkinsonovo boleznijo, zdravljenim z zdravilom Tasmar in pripravki levodope.
Therefore, caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Zato je treba previdno ravnati pri uporabi rivastigmina v kombinaciji z zaviralci receptorjev beta in drugimi zdravili proti bradikardiji (npr. antiaritmiki iz skupine III, antagonisti kalcijevih digitalisovi glikozidi, pilokarpin).
Therefore, caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Zato je treba previdno ravnati pri uporabi rivastigmina v kombinaciji z zaviralci receptorjev beta in drugimi zdravili proti bradikardiji (npr. antiaritmikih iz skupine III, antagonisti kalcijevih digitalisovi glikozidi, pilokarpin).
Therefore, caution should be exercised when rivastigmine is combined with beta-blockers or other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Iz teh razlogov je potrebna previdnost pri uporabi rivastigmina v kombinaciji z antagonisti adrenergičnih receptorjev beta, pa tudi v kombinaciji z drugimi zdravili, ki povzročajo bradikardijo (na primer z antiaritmiki razreda III, antagonisti kalcijevih kanalčkov, glikozidi digitalisa in pilokarpinom).
Therefore, caution should be exercised when rivastigmine is combined with beta.blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents, calcium channel antagonists, digitalis glycoside, pilocarpin).
Iz teh razlogov je potrebna previdnost pri uporabi rivastigmina v kombinaciji z antagonisti adrenergičnih receptorjev beta, pa tudi v kombinaciji z drugimi zdravili, ki povzročajo bradikardijo (na primer z antiaritmiki razreda III, antagonisti kalcijevih kanalčkov, glikozidi digitalisa in pilokarpinom).
Therefore, caution should be exercised when treating patients ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily (see sections 4.8 and 5.2).
Zato je potrebna previdnost pri zdravljenju bolnikov, starih ≥ 65 let, z odmerki, višjimi od 10 mg vortioksetina enkrat na dan (glejte poglavji 4.8 in 5.2).
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).
Zato je pri dajanju visokih odmerkov NSAID-ov ali acetilsalicilne kisline sočasno s pemetreksedom bolnikom z normalnim delovanjem ledvic (očistek kreatinina  80 ml/min) potrebna previdnost.
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).
Zato je pri dajanju visokih odmerkov NSAIDs ali acetilsalicilne kisline sočasno s pemetreksedom bolnikom z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) potrebna previdnost.
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Zato je pri dajanju visokih odmerkov NSAID-ov ali acetilsalicilne kisline sočasno s pemetreksedom bolnikom z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) potrebna previdnost.
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Zato je pri dajanju visokih odmerkov NSAID-ov ali acetilsalicilne kisline sočasno s pemetreksedom bolnikom z normalnim delovanjem ledvic (očistek kreatinina  80 ml/min) potrebna previdnost.
Therefore, caution should be observed when co-administering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Zato je potrebna previdnost med sočasno uporabo zdravila Dynastat in zdravil, ki se presnavljajo pretežno s CYP2D6 in imajo ozko terapevtsko območje (npr. flekainid, propafenon, metoprolol).
Therefore, caution should be recommended when driving a car or operating machinery.
Svetovati jim je treba, naj bodo med vožnjo ali pri upravljanju s stroji previdni.
Therefore, caution should be recommended when driving a car or operating machines.
Zato je treba bolnikom, ki vozijo avto ali uporabljajo stroje, priporočiti previdnost.
Therefore, caution should be taken if these drugs are co-administered with olaparib and patients should be closely monitored.
Zato je v primeru sočasne uporabe teh zdravil in olapariba potrebna previdnost, bolnice pa je potrebno skrbno spremljati.
Therefore, caution should be used when co-administration of eltrombopag with LPV/RTV takes place.
Pri sočasni uporabi eltrombopaga in LPV/RTV je zato potrebna previdnost.
Therefore, caution should be used when prescribing naloxegol to such patients (see section 4.3).
Zato je pri predpisovanju naloksegola takšnim bolnikom potrebna previdnost (glejte poglavje 4.3)
Therefore, caution should be used when treating Chinese patients with Tredaptive co-administered with simvastatin or ezetimibe/simvastatin (particularly simvastatin doses of 40 mg or higher).
Zato je pri zdravljenju kitajskih bolnikov, ki jemljejo zdravilo Tredaptive skupaj s simvastatinom ali z ezetimibom/simvastatinom (zlasti pri odmerkih simvastatina 40 mg ali več) potrebna previdnost.
Therefore, ceritinib should be used with caution in patients who have or may develop prolongation of the QT interval, including those patients taking anti-arrhythmic medicinal products such as class I (e.g. quinidine, procainamide, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics or other medicinal products that may lead to QT prolongation such as astemizole, domperidone, droperidol, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin.
Previdnost je zato potrebna pri uporabi ceritiniba pri bolnikih, ki že imajo podaljšan interval QT ali lahko pri njih pride do podaljšanja intervala QT, vključno z bolniki, ki jemljejo antiaritmična zdravila, kot so antiaritmiki razreda I (npr. kinidin, prokainamid, dizopiramid) ali razreda III (npr. amiodaron, sotalol, dofetilid in ibutilid) ali druga zdravila, ki lahko povzročijo podaljšanje intervala QT, kot so astemizol, domperidon, droperidol, klorokin, halofantrin, klaritromicin, haloperidol, metadon, cisaprid in moksifloksacin.
Therefore, children who weigh at least 33 kg may take either one 200 mg hard capsule daily or the oral solution up to a maximum dose of 240 mg (24 ml), once daily.
Torej lahko otroci s težo najmanj 33 kg, enkrat dnevno vzamejo ali eno 200 mg trdo kapsulo ali maksimalno dozo 240 mg (24 ml) peroralne raztopine.
Therefore, clinical medicinal product interactions are unlikely to occur as a result of ponatinib- mediated inhibition of substrates for these transporters.
Zato ni verjetno, da bi se pojavilo klinično medsebojno delovanje med zdravili kot posledica zaviranja substratov teh prenašalcev, pri katerem posreduje ponatinib.
Therefore, clinical monitoring
bolnikih verjetno treba prilagoditi
Therefore, clinical response to treatment and renal function should be closely monitored (see sections 4.4 and 5.2).
Zato je treba pri teh bolnikih skrbno nadzorovati klinični odziv na zdravljenje in delovanje ledvic (glejte poglavji 4.4 in 5.2).
Therefore, clinical response to treatment and renal function should be closely monitored in patients treated with emtricitabine at prolonged dosing intervals (see sections 4.2 and 5.2).
Zato je potrebno pozorno nadzorovati klinični odziv na zdravljenje in ledvično funkcijo pri bolnikih, ki se zdravijo z emtricitabinom s podaljšanimi intervali odmerjanja (glejte poglavji 4.2 in 5.2).
Therefore, clinically relevant drug-drug interactions with co-medications which are significantly cleared by CYP1A1- mediated biotransformation, such as erlotinib or granisetron cannot be ruled out.
Zato klinično pomembnega medsebojnega delovanja s sočasno uporabljenimi zdravili, ki se izločajo predvsem preko presnove s CYP1A1, kot sta erlotinib ali granisetron, ni mogoče izključiti.
Therefore, clinically relevant interactions would not be expected with other P- glycoprotein/CYP3A4 inhibitors.
Zato niso verjetne klinično pomembne interakcije z drugimi zaviralci P-glikoproteina ali CYP3A4.
Therefore, close clinical surveillance (looking for signs of bleeding or anaemia) is required when dabigatran is co-administered with verapamil.
Zato je treba pri hkratni uporabi dabigatrana in verapamila bolnika natančno klinično spremljati (da bi odkrili znake krvavitve ali anemije).
Therefore, close monitoring of glycaemic control, dose adjustment within the recommended posology and changes in diabetic treatment should be considered when cationic medicinal products that are eliminated by renal tubular secretion are co-administered.
Pri sočasnem jemanju kationskih zdravil, ki se izločajo z ledvično tubularno sekrecijo, je zato treba pretehtati možnost skrbnega spremljanja urejenosti glikemije, prilagoditve odmerkov znotraj priporočenih vrednosti in spremembe zdravljenja sladkorne bolezni.
Therefore, close monitoring of growth in children and adolescents under imatinib treatment is recommended (see section 4.8).
Zato je pri otrocih in mladostnikih, ki prejemajo imatinib, priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
Therefore, close monitoring of growth in children under imatinib treatment is recommended (see section 4.8).
Zato je pri otrocih, ki prejemajo imatinib, priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
Therefore, close monitoring of growth in paediatric patients under treatment with imatinib is recommended (see section 4.8).
Zato je pri pediatričnih bolnikih, ki prejemajo imatinib, priporočeno natančno spremljanje njihove rasti (glejte poglavje 4.8).
Therefore, close safety monitoring is advised. (see sections 4.2 and 5.2)
Priporoča se skrbno spremljanje varnosti zdravila (glejte poglavji 4.2 in 5.2).
Therefore, co-administration of
Sočasna uporaba zdravila
Therefore, co-administration of Entresto with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan.
Iz tega razloga lahko sočasna uporaba zdravila Entresto z zaviralci OATP1B1, OATP1B3, OAT3 (kot sta rifampicin in ciklosporin), OAT1 (kot sta tenofovir in cidofovir) ali MRP2 (kot je ritonavir) poveča sistemsko izpostavljenost substanci LBQ657 oziroma valsartanu.
Therefore, co-administration of ISENTRESS with aluminium and/or magnesium containing antacids is not recommended.
Zato sočasna uporaba zdravila ISENTRESS z antacidi, ki vsebujejo aluminij in/ali magnezij, ni priporočljiva.
Therefore, co-administration of lumacaftor/ivacaftor is not recommended with strong CYP3A inducers.
Zato sočasno dajanje lumakaftorja/ivakaftorja z močnimi spodbujevalci CYP3A ni priporočljivo.
Therefore, co-administration of Neparvis with inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. rifampicin, ciclosporin), OAT1 (e.g. tenofovir, cidofovir) or MRP2 (e.g. ritonavir) may increase the systemic exposure of LBQ657 or valsartan.
Iz tega razloga lahko sočasna uporaba zdravila Neparvis z zaviralci OATP1B1, OATP1B3, OAT3 (kot sta rifampicin in ciklosporin), OAT1 (kot sta tenofovir in cidofovir) ali MRP2 (kot je ritonavir) poveča sistemsko izpostavljenost substanci LBQ657 oziroma valsartanu.
Therefore, co-administration of ONIVYDE with inducers of CYP3A4 may reduce systemic exposure of ONIVYDE.
Zato sočasno dajanje zdravila ONIVYDE in induktorjev encima CYP3A4 lahko zmanjša sistemsko izpostavljenost zdravilu ONIVYDE.
Therefore, co-administration of ONIVYDE with other inhibitors of CYP3A4 (e.g. grapefruit juice, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) may increase systemic exposure of ONIVYDE.
Zato lahko sočasno dajanje zdravila ONIVYDE in drugih zaviralcev encima CYP3A4 (npr. grenivkinega soka, klaritromicina, indinavirja, itrakonazola, lopinavirja, nefazodona, nelfinavirja, ritonavirja, sakvinavirja, telaprevirja, vorikonazola) poveča sistemsko izpostavljenost zdravilu ONIVYDE.
Therefore, co-administration of Senshio with strong enzyme inducers like carbamazepine, phenytoin, St John’s wort and rifabutin would be expected to decrease the exposure of ospemifene, which may decrease the clinical effect.
Zato je pričakovati, da bi sočasna uporaba zdravila Senshio z močnimi induktorji encimov, kot so karbamazepin, fenitoin, šentjanževka in rifabutin, zmanjšala izpostavljenost ospemifenu, kar lahko zmanjša klinični učinek.